<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:mp ids='MP_0004027'>Trisomy</z:mp> 11 in <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) is rare, with undefined clinical significance and is currently assigned to the International Prognostic Scoring System (IPSS) intermediate-risk group </plain></SENT>
<SENT sid="1" pm="."><plain>Over a 15-year period, we identified 17 MDS patients with <z:mp ids='MP_0004027'>trisomy</z:mp> 11 either as a sole abnormality (n=10) or associated with one or two additional alterations (n=7), comprising 0.3% of <z:hpo ids='HP_0000001'>all</z:hpo> <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> cases reviewed </plain></SENT>
<SENT sid="2" pm="."><plain>Of 16 patients with Bone Marrow material available for review, 14 (88%) patients presented with excess blasts, 69% patients evolved to <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) in a 5-month median interval and the median survival was 14 months </plain></SENT>
<SENT sid="3" pm="."><plain>For comparison, we studied 19 AML patients with <z:mp ids='MP_0004027'>trisomy</z:mp> 11 in a noncomplex karyotype, of which, a substantial subset of patients had morphologic <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and/or preexisting cytopenia(s)/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Genomic DNA PCR showed MLL partial tandem duplication in 5 of 10 MDS and 7 of 11 AML patients </plain></SENT>
<SENT sid="5" pm="."><plain>A review of literature identified 17 additional cases of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with <z:mp ids='MP_0004027'>trisomy</z:mp> 11, showing similar clinicopathologic features to our patients </plain></SENT>
<SENT sid="6" pm="."><plain>Compared with our historical data comprising 1165 MDS patients, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients with <z:mp ids='MP_0004027'>trisomy</z:mp> 11 had a significantly inferior survival to patients in the IPSS intermediate-risk cytogenetic group (P=0.0002), but comparable to the poor-risk group (P=0.97) </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that <z:mp ids='MP_0004027'>trisomy</z:mp> 11 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> correlates with clinical <z:hpo ids='HP_0000718'>aggressiveness</z:hpo>, may suggest an early/evolving <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes and is best considered a high-risk cytogenetic abnormality in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> prognostication </plain></SENT>
</text></document>